Does colestipol cause hair loss? This is a question raised by some patients taking bile acid sequestrants for high cholesterol. Colestipol is not routinely licensed in the UK, where cholestyramine and colesevelam are the available alternatives; however, the question of whether these medicines affect hair is clinically relevant. Current UK regulatory evidence — including SmPCs and EMA assessment reports — does not list alopecia as a recognised side effect. This article examines what the evidence shows, explores nutritional factors that may affect hair health during long-term therapy, and explains when to seek advice from your GP or pharmacist.

Colestipol and Hair Loss: What the Evidence Shows

Alopecia is not a recognised adverse effect of bile acid sequestrants according to UK SmPCs or EMA regulatory data, and no causal link between colestipol and hair loss has been established in clinical trials or post-marketing surveillance.

Experiencing these side effects? Our pharmacists can help you navigate them →

Colestipol is a bile acid sequestrant used to lower LDL cholesterol. It works by binding to bile acids in the gastrointestinal tract, preventing their reabsorption and prompting the liver to convert more cholesterol into bile acids — thereby reducing circulating cholesterol levels.

Important note on UK availability: Colestipol is not routinely licensed or marketed in the UK. The bile acid sequestrants currently available in the UK are cholestyramine (e.g., Questran Light) and colesevelam (Cholestagel), both of which have current UK Summaries of Product Characteristics (SmPCs) on the Electronic Medicines Compendium (EMC) and entries in the British National Formulary (BNF). If you have been prescribed colestipol, it is likely to have been sourced as a special or imported medicine; your prescriber or pharmacist can clarify this.

Regarding hair loss specifically, alopecia is not listed as a recognised adverse effect in the UK SmPCs for cholestyramine or colesevelam, nor does it appear as a known side effect in the EMA's European Public Assessment Report (EPAR) for colesevelam (Cholestagel). There is no established causal link between bile acid sequestrant therapy and hair loss in major clinical trials or post-marketing surveillance data available to UK regulators.

That said, individual patient experiences can vary. Some people taking bile acid sequestrants have anecdotally reported changes in hair condition, though these reports have not been substantiated by robust clinical evidence. It is also important to recognise that:

• Hair loss is multifactorial — it can result from stress, hormonal changes, nutritional deficiencies, thyroid disorders, or other medications taken concurrently.

• Correlation does not imply causation — experiencing hair loss whilst taking a bile acid sequestrant does not necessarily mean the medication is responsible.

If you are concerned about hair loss whilst taking colestipol or any bile acid sequestrant, discuss this with your GP or pharmacist rather than stopping the medication abruptly, as doing so could affect your cholesterol management and cardiovascular risk.

Not sure if this is normal? Chat with one of our pharmacists →

Nutrient Deficiencies That May Affect Hair Health

Long-term use of older bile acid resins such as cholestyramine and colestipol can impair absorption of fat-soluble vitamins A, D, E, and K, and deficiencies in vitamin D, iron, or zinc are well-recognised contributors to hair loss.

Although bile acid sequestrants are not directly linked to hair loss, their mechanism of action raises an important consideration: long-term use of older resins such as cholestyramine and colestipol can impair the absorption of fat-soluble vitamins — specifically vitamins A, D, E, and K — as noted in the cholestyramine SmPC. This occurs because these resins can bind not only to bile acids but also to certain nutrients and medications in the gut.

It is worth noting that colesevelam (Cholestagel) has a more selective binding profile and, at usual therapeutic doses, has a lesser impact on fat-soluble vitamin absorption according to its SmPC. The nutritional considerations below are therefore more relevant to cholestyramine and colestipol than to colesevelam.

Of particular relevance to hair health is vitamin D, which plays a role in the hair follicle cycle. Observational studies have found associations between low vitamin D levels and conditions such as alopecia areata and telogen effluvium (diffuse hair shedding), though a direct causal relationship has not been firmly established. Similarly, vitamin A is important for cell growth including hair follicle cells, though both deficiency and excess can contribute to hair changes.

Other nutritional factors that may be relevant include:

• Folate and B vitamins — there is limited evidence that cholestyramine may reduce folate absorption in some individuals; B-vitamin deficiencies are associated with hair thinning, though this is a class caution rather than a well-evidenced effect specific to colestipol.

• Iron — whilst not directly bound by bile acid sequestrants, poor dietary intake combined with any degree of malabsorption can contribute to iron deficiency, a well-established cause of hair loss, particularly in women.

• Zinc — essential for hair tissue growth and repair; deficiency can lead to hair shedding.

Patients on long-term bile acid sequestrant therapy should maintain a varied, balanced diet. Vitamin level testing should be guided by clinical assessment rather than performed routinely; your GP may arrange targeted blood tests — such as a full blood count (FBC), serum ferritin, thyroid-stimulating hormone (TSH), and 25-OH vitamin D if risk factors are present — if you develop symptoms such as fatigue, hair changes, or skin problems.

When to Speak to Your GP or Pharmacist

Consult your GP if hair loss is sudden, patchy, progressive, or accompanied by symptoms such as fatigue, weight changes, or scalp inflammation, as these may indicate an underlying condition requiring investigation.

Whilst hair loss alone is rarely a medical emergency, there are circumstances in which it warrants prompt professional attention — particularly if you are taking a long-term medication such as a bile acid sequestrant.

You should contact your GP if:

• Hair loss is sudden, patchy, or accompanied by other symptoms such as fatigue, unexplained weight changes, or skin changes — these may suggest an underlying thyroid disorder or nutritional deficiency.

• You notice significant or progressive hair thinning that is affecting your quality of life.

• You experience scalp symptoms such as redness, scaling, pustules, pain, or tenderness — these may indicate scarring alopecia or another inflammatory scalp condition that requires prompt dermatological assessment.

• Hair loss is rapidly progressive or involves loss of eyebrows, eyelashes, or body hair.

• You are experiencing other new or unexplained symptoms alongside hair loss, such as muscle weakness, easy bruising, or visual disturbances, which could indicate fat-soluble vitamin deficiency.

• You are considering stopping your bile acid sequestrant due to concerns about side effects — never stop a prescribed medication without medical advice, as this could have implications for your cardiovascular health.

Your GP may arrange initial investigations guided by your history and examination, which commonly include FBC, serum ferritin, and TSH; further tests (such as 25-OH vitamin D, folate, or B12) may be added if clinically indicated. The NHS hair loss guidance and NICE Clinical Knowledge Summaries (CKS) on alopecia provide further information on investigation and referral pathways.

Your pharmacist can help by:

• Reviewing your full medication list to identify any other drugs that may contribute to hair loss (for example, certain antihypertensives, anticoagulants, or hormonal therapies).

• Advising on the correct timing of bile acid sequestrant doses relative to other medications and meals, to minimise nutrient and drug interactions.

• Signposting you to appropriate NHS services or advising whether a GP appointment is warranted.

Early discussion with a healthcare professional ensures that any underlying cause of hair loss is identified and addressed appropriately, rather than attributed to your cholesterol medication without proper investigation.

Managing Side Effects While Taking Bile Acid Sequestrants

The most common side effects of bile acid sequestrants are gastrointestinal, including constipation, bloating, and nausea; other medications should be taken at least one hour before or four to six hours after the resin dose to avoid absorption interactions.

Bile acid sequestrants are generally well tolerated, but like all medicines, they can cause side effects in some individuals. The most commonly reported adverse effects relate to the gastrointestinal system, given that these drugs act locally within the gut. These include:

• Constipation — the most frequently reported side effect, which can often be managed by increasing fluid and dietary fibre intake.

• Bloating, flatulence, and nausea — particularly when starting treatment or increasing the dose.

• Abdominal discomfort — usually mild and transient.

BNF and SmPC guidance recommends starting at a low dose and titrating gradually to improve tolerability. Taking the medication with plenty of water and maintaining adequate hydration throughout the day can also help.

Because bile acid sequestrants — particularly cholestyramine and colestipol — can interfere with the absorption of other medications, it is important to take other drugs at an appropriate interval from the resin dose. As a general guide based on UK SmPC and BNF information:

• Most medicines should be taken at least one hour before or four to six hours after cholestyramine or colestipol.

• Levothyroxine should be separated by at least four hours.

• Warfarin and other narrow-therapeutic-index drugs require particular care; always check the individual SmPC or seek pharmacist advice.

• Colesevelam (Cholestagel) has a different and generally more favourable interaction profile — refer to its SmPC and the BNF for specific guidance, as co-administration rules differ from those for older resins.

Note also that bile acid sequestrants can raise triglyceride levels in some patients; this is noted in the BNF and relevant SmPCs and should be monitored where clinically appropriate.

For patients concerned about nutritional status during long-term therapy, the following practical steps are recommended:

• Eat a varied, balanced diet with plenty of vegetables, lean proteins, and healthy fats to support overall nutrient intake.

• Discuss vitamin supplementation with your GP if blood tests reveal deficiencies — self-prescribing high-dose fat-soluble vitamins without guidance is not advisable and may be harmful.

• Attend regular medication reviews as recommended by your GP or practice pharmacist to ensure your treatment remains appropriate and well managed.

Addressing side effects proactively supports long-term adherence to cholesterol-lowering therapy, which is important for reducing cardiovascular risk in line with NICE guidance on lipid modification (NICE NG238).

MHRA Guidance and Reporting Unexpected Symptoms

Alopecia is not listed in UK regulatory documents for licensed bile acid sequestrants, but any unexpected symptom including hair loss should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK body responsible for ensuring that medicines are safe and effective. The MHRA continuously monitors the safety of licensed medicines through post-marketing surveillance, which includes reviewing reports submitted by both healthcare professionals and patients.

Alopecia is not listed as a recognised adverse effect in the UK SmPCs for the bile acid sequestrants currently licensed in the UK (cholestyramine and colesevelam). For colesevelam specifically, the EMA's European Public Assessment Report (EPAR) for Cholestagel does not identify hair loss as a known side effect. This does not mean that individual experiences are invalid, but it does indicate that a causal relationship has not been established through available regulatory evidence.

If you experience an unexpected symptom — including hair loss — whilst taking a bile acid sequestrant, you are encouraged to report it through the MHRA's Yellow Card scheme (available at yellowcard.mhra.gov.uk). The Yellow Card scheme allows patients and healthcare professionals to report suspected side effects, helping the MHRA to identify any emerging safety signals. Reporting is straightforward and can be done online, by phone, or via the Yellow Card app.

Key points to remember:

• Reporting a suspected side effect does not mean the medicine is definitely responsible — it contributes to ongoing safety monitoring.

• Your report could help protect other patients by identifying previously unrecognised risks.

• Always inform your GP or pharmacist if you submit a Yellow Card report, so that your care can be coordinated appropriately.

Engaging with pharmacovigilance systems such as the Yellow Card scheme is an important part of responsible medicine use and supports the broader goal of patient safety across the NHS.

Frequently Asked Questions